Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
45 studies found for:    "Microscopic polyangiitis"
Show Display Options
RSS Create an RSS feed from your search for:
"Microscopic polyangiitis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
Conditions: Polyarteritis Nodosa;   Microscopic Polyangiitis
Interventions: Drug: azathioprine;   Drug: cyclophosphamide
2 Active, not recruiting
Has Results
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Drug: Rituximab
3 Recruiting Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   Wegener's
Intervention:
4 Completed CellCept in p-ANCA Vasculitis
Conditions: MPO-ANCA Vasculitis;   Microscopic Polyangiitis
Intervention: Drug: CellCept (mycophenolate mofetil)
5 Recruiting A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
Condition: Wegener's Granulomatosis or Microscopic Polyangiitis
Interventions: Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Rituximab
6 Completed
Has Results
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group);   Drug: Cyclophosphamide plus rituximab placebo (control group);   Drug: Azathioprine;   Drug: Methylprednisolone (or other glucocorticoid);   Drug: Prednisone
7 Recruiting A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Granulomatosis With Polyangiitis
Intervention: Drug: Rituximab
8 Withdrawn BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Blisibimod;   Drug: Placebo
9 Completed Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
Conditions: MPA;   PAN or EGPA With FFS=0;   At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
Interventions: Drug: corticosteroid and azathioprine;   Drug: corticosteroid and placebo
10 Completed Efficacy Study of Two Treatments in the Remission of Vasculitis
Conditions: Wegener's Granulomatosis,;   Microscopic Polyangiitis
Interventions: Drug: Rituximab;   Drug: Azathioprine
11 Terminated Plasma Exchange for Renal Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Procedure: Plasma exchange;   Drug: Intravenous methyl prednisolone;   Drug: Methyl prednisolone
12 Active, not recruiting Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA);   Microscopic Polyangiitis (MPA)
Interventions: Procedure: Plasma Exchange;   Drug: Glucocorticoids
13 Recruiting Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
Conditions: Granulomatosis, Wegener's;   Microscopic Polyangiitis
Intervention: Other: blood specimen
14 Unknown  Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Glucocorticoids;   Drug: Rituximab
15 Enrolling by invitation Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Other: Observational
16 Active, not recruiting PRO Development for ANCA Associated Vasculitis
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome
Intervention:
17 Active, not recruiting Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   Renal Limited Forms
Interventions: Drug: Rituximab (Arm B);   Drug: Rituximab (Arm A)
18 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
19 Active, not recruiting Rituximab Vasculitis Maintenance Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Biological: Rituximab;   Drug: Azathioprine
20 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.